[HTML] thelancet.com

[HTML][HTML] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - thelancet.com
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …
被引用次数：437 相关文章
[PDF] qub.ac.uk

[PDF][PDF] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet, A Loblaw… - 2019 - pureadmin.qub.ac.uk
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …
[HTML] nih.gov

[HTML][HTML] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - ncbi.nlm.nih.gov
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …
[PDF] academia.edu

[PDF][PDF] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet, A Loblaw… - 2019 - academia.edu
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …
[HTML] sciencedirect.com

[HTML][HTML] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - Elsevier
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - Lancet …, 2019 - pure.qub.ac.uk
BACKGROUND: Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet, A Loblaw… - 2019 - repository.icr.ac.uk
BACKGROUND: Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

[引用][C] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - cir.nii.ac.jp
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for
prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label …

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - europepmc.org
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …